SCHEMBL13129296

SCHEMBL13129296

CCCC(=O)CCC(=O)NC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.46
HDAC3 O15379 4/20 0.44
HDAC1 Q13547 4/20 0.44
HDAC2 Q92769 4/20 0.44
HDAC8 Q9BY41 4/20 0.44
HDAC6 Q9UBN7 1/20 0.44
CTSD P07339 1/20 0.42
POLB P06746 1/20 0.39
CES2 O00748 1/20 0.39
CES1 P23141 1/20 0.39
FFAR3 O14843 3/20 0.38
TSHR P16473 1/20 0.36
MCL1 Q07820 1/20 0.36
CASP2 P42575 1/20 0.35
ALDH1A1 P00352 1/20 0.35
KDM4E B2RXH2 1/20 0.34
KDM5C P41229 1/20 0.34
EGLN1 Q9GZT9 1/20 0.34
PHF8 Q9UPP1 1/20 0.34
KDM2A Q9Y2K7 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL42695 0.84
SCHEMBL4093803 0.82 LMNA (0.48) LMNAHDAC3HDAC1HDAC2HDAC8
SCHEMBL7369730 0.82 HDAC3 (0.46) LMNAHDAC3HDAC1HDAC2HDAC8
SCHEMBL6522181 0.81
SCHEMBL5829953 0.81
Water SCHEMBL8723987 0.81 HDAC3 (0.57) LMNAHDAC3HDAC1HDAC2HDAC8
SCHEMBL106749 0.81
Hydrochloric Acid SCHEMBL5038099 0.81
Water SCHEMBL8723991 0.81
SCHEMBL3660629 0.81 LMNA (0.63) LMNAHDAC3HDAC1HDAC2HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230285570-A1 THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM CORNELL UNIVERSITY 2023-09-14 US disclosed
US-20230277553-A1 THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE CORNELL UNIVERSITY 2023-09-07 US disclosed
US-20100239659-A1 SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTI-CANCER AGENTS ALLEXCEL., INC. (US) 2010-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230285570-A1 THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM XIAP, CUL4A, CUL1 LMNA 1674/4885HDAC3 1495/4885HDAC1 957/4885
US-20100239659-A1 SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTI-CANCER AGENTS CD44, EPCAM, EGFR LMNA 2786/4885HDAC3 1815/4885HDAC1 3230/4885
US-20230277553-A1 THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE BET1, BRD4, PHKB LMNA 1366/4885HDAC3 275/4885HDAC1 158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.